Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Ovarian Neoplasms × Standard of Care × Clear all

Phase

Phase NA 7 Phase 2 3 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 7 Breast Neoplasms 7 Lung Neoplasms 5 Head and Neck Neoplasms 5 Neoplasms 4 Leukemia, Myeloid, Acute 4 Hematologic Neoplasms 3 Colorectal Neoplasms 3 Recurrence 2 Pulmonary Disease, Chronic Obstructive 2 Neoplasm Metastasis 2 Leukemia 2 Colonic Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Xerostomia 1 Urologic Neoplasms 1 Urologic Diseases 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Urinary Bladder Diseases 1 Teratoma 1 Stroke 1 Stomatitis 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Radiation Injuries 1 Prostatic Diseases 1

Interventions

Paclitaxel 67 Carboplatin 56 Bevacizumab 28 liposomal doxorubicin 23 Topotecan 22 Gemcitabine 18 olaparib 16 Cisplatin 13 Doxorubicin 12 Drug Therapy 11 Taxes 10 niraparib 9 Docetaxel 6 Trabectedin 5 CP protocol 5 avelumab 4 atezolizumab 4 Immunoglobulin G 4 Ifosfamide 4 Hyperthermic Intraperitoneal Chemotherapy 4 Disulfides 4 Dexamethasone 4 Cyclophosphamide 4 Chemotherapy, Adjuvant 4 1-dodecylpyridoxal 4 trebananib 3 pembrolizumab 3 fluzoparib 3 dostarlimab 3 cediranib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03602859 2025-12-31

FIRST

Tesaro, Inc.

Phase 3 Active not recruiting

1,400 enrolled 18 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡